
## Liang Li

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4344333/publications.pdf Version: 2024-02-01



LIANCL

#	Article	IF	CITATIONS
1	FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research, 2022, 28, 4629-4633.	7.0	16
2	FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clinical Cancer Research, 2020, 26, 532-536.	7.0	58
3	Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer. European Journal of Clinical Pharmacology, 2020, 76, 589-601.	1.9	5
4	Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis. European Journal of Clinical Pharmacology, 2019, 75, 1521-1532.	1.9	2
5	Model-based meta-analysis of the effects of non-selective and α1-selective GABAA receptor agonists in healthy volunteers. European Journal of Clinical Pharmacology, 2015, 71, 1209-1221.	1.9	6